お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:非アルコール性脂肪肝疾患治療薬の世界市場:2018年~2022年
市場調査レポート
商品コード
722959

非アルコール性脂肪肝疾患治療薬の世界市場:2018年~2022年

Global Non-alcoholic Fatty Liver Disease Therapeutics Market 2018-2022

出版日: | 発行: TechNavio (Infiniti Research Ltd.) | ページ情報: 英文 111 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.25円
非アルコール性脂肪肝疾患治療薬の世界市場:2018年~2022年
出版日: 2018年10月05日
発行: TechNavio (Infiniti Research Ltd.)
ページ情報: 英文 111 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

非アルコール性脂肪肝疾患について

非アルコール性脂肪肝疾患は、過剰な脂肪が肝臓に蓄積されている状態です。 NAFLDには、単純脂肪肝と非アルコール性脂肪性肝炎の2種類があります。単純性脂肪肝では、肝臓の脂肪は非常に少なく、炎症や肝細胞の損傷はありません。

Technavioのアナリストは、2018年から2022年に世界の非アルコール性脂肪肝疾患治療薬市場が16.19%のCAGRで成長すると予測しています。

当レポートでは、世界の非アルコール性脂肪肝疾患治療薬市場について調査分析し、市場規模と成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 調査範囲

第3章 調査方法

第4章 市場状況

  • 市場のエコシステム
  • 市場特性
  • 市場セグメンテーション分析

第5章 市場規模

  • 市場の定義
  • 市場規模(2017年)
  • 市場規模および予測(2017-2022年)

第6章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代替品の脅威
  • 競争相手の脅威
  • 市場状況

第7章 パイプライン情勢

第8章 市場セグメンテーション:投与経路別

  • セグメンテーション:投与経路別 (2017-2022年)
  • 比較:投与経路別
  • 経口
  • 非経口
  • 市場機会:投与経路

第9章 顧客情勢

第10章 地域情勢

  • 地域別セグメンテーション(2017-2022年)
  • 地域比較
  • 南北アメリカ
  • 欧州・中東・アフリカ地域
  • アジア太平洋地域
  • 市場機会

第11章 意思決定の枠組み

第12章 成長要因と課題

  • 市場の成長要因
  • 市場の課題

第13章 市場動向

第14章 ベンダー情勢

  • 概要
  • 創造的破壊の状況

第15章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • ALLERGAN
  • GlaxoSmithKline
  • Merck
  • Novartis
  • Pfizer

第16章 付録

  • 略語のリスト
目次
Product Code: IRTNTR23695

About Non-alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease is a condition in which excess fat is stored in the liver. There are two types of NAFLD, namely simple fatty liver and non-alcoholic steatohepatitis. In simple fatty liver, the fat in the liver is very less and there is no inflammation or liver cell damage.

Technavio's analysts forecast the Global Non-alcoholic Fatty Liver Disease Therapeutics Market to grow at a CAGR of 16.19% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the non-alcoholic fatty liver disease therapeutics market. To calculate the market size, the report considers the revenue generated by the applications of non-alcoholic fatty liver disease therapeutics across the globe.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Non-alcoholic Fatty Liver Disease Therapeutics Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • ALLERGAN
  • GlaxoSmithKline
  • Merck
  • Novartis
  • Pfizer

Market driver

  • Increasing prevalence of non-alcoholic fatty liver disease
  • For a full, detailed list, view our report

Market challenge

  • Unclear pathogenesis of non-alcoholic fatty liver disease
  • For a full, detailed list, view our report

Market trend

  • Growing number of strategic alliances
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2017
  • Market size and forecast

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: PIPELINE LANDSCAPE

PART 08: MARKET SEGMENTATION BY ROA

  • Segmentation by RoA
  • Comparison by RoA
  • Oral RoA - Market size and forecast 2017-2022
  • Parenteral RoA - Market size and forecast 2017-2022
  • Market opportunity by RoA

PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • NAFLD therapeutics market in the Americas - Market size and forecast 2017-2022
  • NAFLD therapeutics market in EMEA - Market size and forecast 2017-2022
  • NAFLD therapeutics market in APAC - Market size and forecast 2017-2022
  • Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 13: MARKET TRENDS

PART 14: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 15: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • ALLERGAN
  • GlaxoSmithKline
  • Merck
  • Novartis
  • Pfizer

PART 16: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Parent market
  • Exhibit 02: Global metabolic disorders therapeutics market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition: Inclusions and exclusions checklist
  • Exhibit 06: Market size 2017
  • Exhibit 07: Validation techniques employed for market sizing 2017
  • Exhibit 08: Global NAFLD therapeutics market - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 09: Global NAFLD therapeutics market - Year-over-year growth 2018-2022 (%)
  • Exhibit 10: Five forces analysis 2017
  • Exhibit 11: Five forces analysis 2022
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition: Five forces 2017
  • Exhibit 18: Pipeline landscape by development phase 2017-2018
  • Exhibit 19: Late-stage pipeline molecules for the treatment of NAFLD 2017-2018
  • Exhibit 20: Global NAFLD therapeutics market - Market share by RoA 2017-2022 (%)
  • Exhibit 21: Comparison by RoA
  • Exhibit 22: Global NAFLD therapeutics market by oral RoA - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 23: Global NAFLD therapeutics market by oral RoA - Year-over-year growth 2018-2022 (%)
  • Exhibit 24: Global NAFLD therapeutics market by parenteral RoA - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 25: Global NAFLD therapeutics market by parenteral RoA - Year-over-year growth 2018-2022 (%)
  • Exhibit 26: Market opportunity by RoA
  • Exhibit 27: Customer landscape
  • Exhibit 28: Global NAFLD therapeutics market by geography - Market share 2017-2022 (%)
  • Exhibit 29: Regional comparison
  • Exhibit 30: NAFLD therapeutics market in Americas - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 31: NAFLD therapeutics market in Americas - Year-over-year growth 2018-2022 (%)
  • Exhibit 32: Top 3 countries in Americas
  • Exhibit 33: NAFLD therapeutics market in EMEA - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 34: NAFLD therapeutics market in EMEA - Year-over-year growth 2018-2022 (%)
  • Exhibit 35: Top 3 countries in EMEA
  • Exhibit 36: NAFLD therapeutics market in APAC - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 37: NAFLD therapeutics market in APAC - Year-over-year growth 2018-2022 (%)
  • Exhibit 38: Top 3 countries in APAC
  • Exhibit 39: Market opportunity
  • Exhibit 40: Vendor landscape
  • Exhibit 41: Landscape disruption
  • Exhibit 42: Vendors covered
  • Exhibit 43: Vendor classification
  • Exhibit 44: Market positioning of vendors
  • Exhibit 45: ALLERGAN: Overview
  • Exhibit 46: ALLERGAN - Business segments
  • Exhibit 47: ALLERGAN - Organizational developments
  • Exhibit 48: ALLERGAN - Geographic focus
  • Exhibit 49: ALLERGAN - Segment focus
  • Exhibit 50: ALLERGAN - Key offerings
  • Exhibit 51: ALLERGAN - Key customers
  • Exhibit 52: GlaxoSmithKline: Overview
  • Exhibit 53: GlaxoSmithKline - Business segments
  • Exhibit 54: GlaxoSmithKline - Organizational developments
  • Exhibit 55: GlaxoSmithKline - Geographic focus
  • Exhibit 56: GlaxoSmithKline - Segment focus
  • Exhibit 57: GlaxoSmithKline - Key offerings
  • Exhibit 58: GlaxoSmithKline - Key customers
  • Exhibit 59: Merck- Overview
  • Exhibit 60: Merck- Business segments
  • Exhibit 61: Merck- Organizational developments
  • Exhibit 62: Merck- Geographic focus
  • Exhibit 63: Merck- Segment focus
  • Exhibit 64: Merck- Key offerings
  • Exhibit 65: Merck- Key customers
  • Exhibit 66: Novartis - Overview
  • Exhibit 67: Novartis - Business segments
  • Exhibit 68: Novartis - Organizational developments
  • Exhibit 69: Novartis - Geographic focus
  • Exhibit 70: Novartis - Segment focus
  • Exhibit 71: Novartis - Key offerings
  • Exhibit 72: Novartis - Key customers
  • Exhibit 73: Pfizer: Overview
  • Exhibit 74: Pfizer - Business segments
  • Exhibit 75: Pfizer - Organizational developments
  • Exhibit 76: Pfizer - Geographic focus
  • Exhibit 77: Pfizer - Segment focus
  • Exhibit 78: Pfizer - Key offerings
  • Exhibit 79: Pfizer - Key customers
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.